Literature DB >> 19136931

Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas.

Cecile Meier1, Sylvia Hoeller, Caroline Bourgau, Petra Hirschmann, Juerg Schwaller, Philip Went, Stefano A Pileri, Andreas Reiter, Stephan Dirnhofer, Alexandar Tzankov.   

Abstract

The Janus kinase 2 (JAK2)-signal transducers and activators of transcription (STAT) pathway plays an important role in hematological malignancies. Mutations and translocations of the JAK2 gene, mapped at 9p24, lead to constitutive activation of JAK2 and its downstream targets. The presence of JAK2 mutations in lymphomas has been addressed in larger cohorts, but there are little systemic data on numerical and structural JAK2 aberrations in lymphoid neoplasms. To study the molecular epidemiology of these aberrations and the consecutive activation of the JAK2-STAT pathway in lymphomas, we examined 527 cases, covering the most common entities, in a tissue microarray by fluorescent in situ hybridization with breakable JAK2 probes, and immunohistochemistry for phosphorylated JAK2 (pJAK2) and its preferred downstream pSTAT3 and pSTAT5. 9p24 gains were detected in 6/17 (35%) primary mediastinal B-cell lymphomas (PMBCLs), 25/77 (33%) Hodgkin's lymphomas (HLs), 3/16 (19%) angioimmunoblastic T-cell lymphomas (AILTs) and 1/5 ALK1(+) anaplastic large cell lymphomas (ALCLs); breaks were observed only in three cases. pJAK2 expression was most prevalent in PMBCL, peripheral T-cell lymphomas and HL. pSTAT3 predominated in ALCLs, HLs, AILTs, PMBCLs and peripheral T-cell lymphomas. pSTAT5 expression was detected frequently in follicular lymphomas, diffuse large B-cell lymphomas and AILTs. 9p24 gains correlated with increased proportions of tumor cells expressing pJAK2 (P=0.002) and pSTAT3 (P=0.001). In follicular lymphomas, concomitant expression of pJAK2 and pSTAT5 was linked to better prognosis, whereas expression of pSTAT3 in nongerminal center-like diffuse large B-cell lymphomas could identify a patient group with an inferior outcome. Our findings stress that despite the rarity of activating JAK2 mutations in lymphomas, JAK2 is recurrently targeted by numerical, and rarely by structural, genetic aberrations in distinct lymphoma subtypes and that JAK2-STAT pathway may play a role in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19136931     DOI: 10.1038/modpathol.2008.207

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  29 in total

1.  STAT3 Inhibition Induces Apoptosis in Cancer Cells Independent of STAT1 or STAT2.

Authors:  Adetola Shodeinde; Kalyani Ginjupalli; H Dan Lewis; Sheraz Riaz; Beverly E Barton
Journal:  J Mol Biochem       Date:  2013-02-20

2.  Immunohistochemical detection of phosphorylated JAK-2 and STAT-5 proteins and correlation with erythropoietin receptor (EpoR) expression status in human brain tumors.

Authors:  M Kondyli; G Gatzounis; A Kyritsis; J Varakis; M Assimakopoulou
Journal:  J Neurooncol       Date:  2010-03-25       Impact factor: 4.130

Review 3.  HiJAKing the epigenome in leukemia and lymphoma.

Authors:  Amanda C Drennan; Lixin Rui
Journal:  Leuk Lymphoma       Date:  2017-04-12

4.  Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma.

Authors:  Chi Young Ok; Jiayu Chen; Zijun Y Xu-Monette; Alexandar Tzankov; Ganiraju C Manyam; Ling Li; Carlo Visco; Santiago Montes-Moreno; Karen Dybkær; April Chiu; Attilio Orazi; Youli Zu; Govind Bhagat; Kristy L Richards; Eric D Hsi; William W L Choi; J Han van Krieken; Jooryung Huh; Xiaoying Zhao; Maurilio Ponzoni; Andrés J M Ferreri; Francesco Bertoni; John P Farnen; Michael B Møller; Miguel A Piris; Jane N Winter; L Jeffrey Medeiros; Ken H Young
Journal:  Clin Cancer Res       Date:  2014-08-14       Impact factor: 12.531

5.  Genetic alterations of 9p24 in lymphomas and their impact for cancer (immuno-)therapy.

Authors:  Thomas Menter; Alexandar Tzankov
Journal:  Virchows Arch       Date:  2018-08-21       Impact factor: 4.064

Review 6.  The promise of Janus kinase inhibitors in the treatment of hematological malignancies.

Authors:  Emilee Senkevitch; Scott Durum
Journal:  Cytokine       Date:  2016-10-27       Impact factor: 3.861

Review 7.  Molecular genetics of childhood, adolescent and young adult non-Hodgkin lymphoma.

Authors:  Rodney R Miles; Rikin K Shah; J Kimble Frazer
Journal:  Br J Haematol       Date:  2016-03-11       Impact factor: 6.998

8.  Activation of Stat3 in renal tumors.

Authors:  Charles Guo; Guanyu Yang; Kyle Khun; Xiantian Kong; David Levy; Peng Lee; Jonathan Melamed
Journal:  Am J Transl Res       Date:  2009-02-28       Impact factor: 4.060

9.  New developments in the pathology of malignant lymphoma: a review of the literature published from January to August 2009.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2009-09-26       Impact factor: 0.196

10.  Histone H2AX suppresses translocations in lymphomas of Eμ-c-Myc transgenic mice that contain a germline amplicon of tumor-promoting genes.

Authors:  Angela Fusello; Julie Horowitz; Katherine Yang-Iott; Brenna L Brady; Bu Yin; Marta A W Rowh; Eric Rappaport; Craig H Bassing
Journal:  Cell Cycle       Date:  2013-08-08       Impact factor: 4.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.